INTRODUCTION
============

Primary arteriovenous fistula (AVF) is the best vascular access for haemodialysis (HD) patients. Despite technical progress, the early failure rate of AVFs (within 3 months of creation) still averages 20--30% \[[@sfz064-B1]\], with higher percentages (50--60%) in fragile patients \[[@sfz064-B2]\]. Currently there are no unique parameters that can predict AVF failure risk, but recent papers highlight AVF blood flow (Qa) as a key parameter to identify a high risk for new AVFs deserving urgent revision to avoid thrombosis \[[@sfz064-B3]\]. Since early detection and pre-emptive repair improve long-term AVF outcome, close monitoring of Qa is mandatory, in particular, in patients with predictably slow and difficult AVF maturation (e.g. late referrals, elderly or diabetics) \[[@sfz064-B6], [@sfz064-B7]\]. However, Doppler ultrasound (DU), the gold standard technique to monitor AVF Qa, although non-invasive, reliable and applicable in any patient at any stage of maturation, is costly, requires a skilled operator with adequate equipment and is not commonly available in all dialysis units. Therefore, alternative first-line methods to measure Qa would be welcomed.

We describe here a new method to estimate Qa that relies on the evaluation of blood oxygen saturation and thus requires only a blood gas analyser, a device much more commonly available in nephrology and dialysis units. This low-cost, non-invasive technique could benefit patients dialysed through a central venous catheter (CVC) before AVF creation and during its maturation.

MATERIALS AND METHODS
=====================

Rationale
---------

We reasoned that once an AVF is created, some increase in central venous oxygen saturation (ScvO~2~) would be observed, likely proportional to the Qa ([Figure 1](#sfz064-F1){ref-type="fig"}). We thus believed that in patients receiving dialysis through a CVC, we could detect changes in ScvO~2~. Moreover, manual compression of the AV shunt is expected to produce quick changes in blood oxygenation such that the differences in ScvO~2~ could be used to infer Qa.

![(**A**) With jugular CVC, we have an easy access to ScvO~2~. (**B**) When AVF is created, we have a change of ScvO~2~ proportional to AVF shunt.](sfz064f1){#sfz064-F1}

Patient selection
-----------------

Eligibility criteria for this study were age ≥18 years, chronic HD treatment by means of a permanent jugular CVC, the presence of an AVF and no evidence of acute underlying illness. Exclusion criteria were evidence of a displaced or malfunctioning CVC, chronic obstructive pulmonary disease or arterial oxygen saturation (SaO~2~) \< 90% in resting condition and severe refractory anaemia (haemoglobin \<9 g/dL despite adequate erythropoietin and iron supplement therapy).

From January to December 2017 we enrolled all patients in our unit who had both a CVC and AVF that fulfilled the eligibility criteria and, in particular, who had capillary SaO~2~ \>90% as measured from any finger of the non-AVF arm \[peripheral pulse oximeter (Max Puls Two; EuroSanitas, Montecatini-Terme Pistoia, Italy); accuracy 2%\].

In all patients before each of the weekly dialysis sessions, we measured blood oxygen (GEM 4000 Premier; Instrumentation Laboratory, Milan, Italy; SO~2~ accuracy 2%) from the CVC 'arterial' branch both before and after 30 s of AVF closure. AVF flow interruption was obtained soon after heparin administration by manually compressing the AVF 1 cm distal to the anastomosis. Effective flow interruption was confirmed by verifying the disappearance of the bruit with a phonendoscope.

The change in ScvO~2~ (ΔScvO~2~) was the difference between ScvO~2~ with the AVF open and ScvO~2~ with the AVF closed. In each patient the Qa was then measured by DU within a maximum of 24 h, with the DU operator blinded to the ScvO~2~ results. In three patients the same measurements were repeated in five consecutive dialysis sessions, by different nurses, to verify the repeatability of the method. In one patient, measurements were repeated after 1 week and after 1, 2 and 3 months of AVF creation to verify Qa changes along with AVF maturation.

The present study is a subanalysis of the 'Studio No. 107055/2017' approved by the Ethics Committee of the ASL Rm2 and was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

RESULTS
=======

We included 18 CVC--AVF patients (10 male and 8 female, age 63.2 ± 15 years, HD vintage 19.8 ± 15 months, SaO~2~ range 93--99%; [Table 1](#sfz064-T1){ref-type="table"}). ScvO~2~ before AVF closure averaged 70.5 ± 3% and ScvO~2~ after AVF closure averaged 65.2 ± 3%. This last value is indeed lower than normal (ScvO~2~ normal value 70%), but is in agreement with those observed in HD patients \[[@sfz064-B8]\]. As a result, ΔScvO~2~ averaged 5.1 ± 3% (range 1--12). AVF Qa measured with DU averaged 635 ± 349 mL/min (range 50--1300) and was strictly and positively correlated with ΔScvO~2~ (*r* = 0.954, P \< 0.0001). We thus considered that we could estimate AVF flow (eQa) as a function of ΔScvO~2~ with the following linear regression model equation ([Figure 2](#sfz064-F2){ref-type="fig"}):

![Correlation test of ΔScvO~2~ and Qa evaluated with DU.](sfz064f2){#sfz064-F2}

###### 

Clinical and biochemical characteristics of the population

  Patients                                       *n* = 18
  --------------------------------------- ----------------------
  Male/female, *n*                                 10/8
  Age (years)                                   63.2 ± 15
  HD vintage (months)                           19.8 ± 15
  AVF vintage (months)                          2.5 ± 2.2
  BMI (kg/m^2^)                                 25.1 ± 1.2
  ABI                                           0.7 ± 0.1
  Haemoglobin (g/dL)                            10.1 ± 1.1
  *K* ~t~/*V*                                   1.48 ± 0.0
  nPCR (g/kg/day)                               1.03 ± 0.0
  SaO~2~ (%), mean ± SD (range)            96.8  ± 0.1 (99--93)
  ScvO~2~ AVF closed (%)                        65.2 ± 3.2
  ScvO~2~ AVF opened (%)                        70.5 ± 3.3
  ΔScvO~2~ (%), mean ± SD (range)           5.1 ±  3.1 (1--12)
  Qa (mL/min via DU), mean ± SD (range)    635 ± 349 (50--1300)

Values are presented as mean ± SD unless stated otherwise. BMI, body mass index; ABI, ankle brachial index; *Kt/V*, urea clearance (*K*) multiplied by dialysis time (*t*) divided by the volume of water in the body; nPCR, normalized protein catabolic rate; Qa, vascular access flow.

eQa = 45.82 + 111.54·ΔScvO~2~

No side effect was recorded secondary to the procedure. In the three patients who had ΔScvO~2~ measured five consecutive times, the maximum calculated difference was \<6.6%, pointing to substantial stability and repeatability of the parameter. In the patient who was sampled after 1 week and 1, 2 and 3 months from AVF creation, ΔScvO~2~ values were 1.6% (eQa 224 mL/min), 2.7% (eQa 346 mL/min), 3.6% (eQa 440 mL/min) and 3.5% (eQa 430 mL/min), respectively, consistent with the corresponding DU Qa values of 220, 330, 390 and 380 mL/min, respectively ([Figure 3](#sfz064-F3){ref-type="fig"}).

![AVF maturation over time for one patient. DU Qa, eQa and ΔScvO~2~ were evaluated at 7, 30, 60 and 90 days after AVF creation with a strictly concordant trend.](sfz064f3){#sfz064-F3}

DISCUSSION
==========

Our study shows that in patients with a CVC and AVF, it is possible to estimate AVF Qa by means of ΔScvO~2~ measurement, which could thus represent a new tool in monitoring vascular access maturation. Since AVF Qa assessment is required to identify an AVF at risk of failure, having a first-line screening method to identify an AVF with a reduced Qa deserving urgent DU seems useful. Indeed, as shown in [Figure 2](#sfz064-F2){ref-type="fig"}, ΔScvO~2~ values of ∼3% indicate flows of ∼300 mL/min, which is the threshold value for an AVF at increased risk of thrombosis. Furthermore, unlike other methods for measuring Qa during an HD session, this method can be used during AVF maturation without positioning fistula needles, before the AVF is ready for venipuncture. For this reason, our simple, cheap, repeatable, non-invasive and operator-independent approach seems to be a useful screening tool to monitor AVF flow and maturation without dedicated instruments and expert operators. It helps to quickly identify patients in urgent need of DU verification and possible surgical revision. Regrettably, and as a limitation, it is applicable only in patients with a CVC.
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